Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed...

|About: Alnylam Pharmaceuticals, Inc. (ALNY)|By:, SA News Editor

Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed ALN-TTR02, a potential treatment for a genetic mutation of the transthyretin gene, reduced serum TTR protein levels in a way that was "rapid, dose dependent, durable, and specific after just a single dose."